With syngeneic subcutaneous and metastatic tumor models, we demonstrate in this study significantly enhanced and cooperative therapeutic effects against melanoma with the combination of the sMIC-clearing antibody B105 and PDL1/PD1 pathway blockade. The gene discussed is CD274; the disease is melanoma.